Transforming Nanomedicines from Lab Scale Production to Novel Clinical Modality

Dalit Landesman-Milo, Dan Peer

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations

Abstract

The use of nanoparticles as anticancer drug carriers has been studied for over 50 years. These nanoparticles that can carry drugs are now termed "nanomedicines". Since the approval of the first FDA "nanodrug", DOXIL in 1995, tremendous efforts have been made to develop hundreds of nanomedicines based on different materials. The development of drug nanocarriers (NCs) for cancer therapy is especially challenging and requires multidisciplinary approach. Not only is the translation from a lab scale production of the NCs to clinical scale a challenge, but tumor biology and its unique physiology also possess challenges that need to be overcome with cleverer approaches. Yet, with all the efforts made to develop new strategies to deliver drugs (including small molecules and biologics) for cancer therapy, the number of new NCs that are reaching clinical trials is extremely low. Here we discuss the reasons most of the NCs loaded with anticancer drugs are not likely to reach the clinic and emphasize the importance of understanding tumor physiology and heterogeneity, the use of predictive animal models, and the importance of sharing data as key denominators for potential successful translation of NCs from a bench scale into clinical modality for cancer care. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)855-862
Number of pages8
JournalBioconjugate chemistry
Volume27
Issue number4
DOIs
StatePublished - Apr 20 2016

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Transforming Nanomedicines from Lab Scale Production to Novel Clinical Modality'. Together they form a unique fingerprint.

Cite this